Goair

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Goair

Quick Facts

Property Description
Active ingredient Xylometazoline hydrochloride
Form Aqueous Solution (Nasal drop or spray)
Pharmacological class Nasal Decongestant (Sympathomimetic)
Common use Temporary relief of nasal congestion
Origin Synthetic (Imidazoline derivative)

What Type of Medicine is Goair and What is its Core Ingredient?

Goair is an Over-The-Counter (OTC) pharmaceutical product classified as a rapid-acting Nasal Decongestant, a category used for symptomatic relief. Its medicinal activity is centered on the single active ingredient, Xylometazoline hydrochloride. This compound is chemically characterized as a sympathomimetic agent and an imidazoline derivative. Xylometazoline is used for addressing the physical discomfort of blocked nasal passages.

As a dedicated nasal agent, Goair is designed for topical use, which concentrates its effect directly at the site of congestion rather than relying on systemic absorption. This preparation is typically formulated as a sterile aqueous solution. Similar popular decongestants containing this same active ingredient, such as Otrivin, share this core formulation principle, focusing on direct application for rapid onset.

Goair's Form, Origin, and General Purpose

Goair is supplied as an aqueous solution administered via a liquid nasal drop or nasal spray. The general purpose of the product is the temporary relief of restricted airflow caused by nasal congestion, often experienced during a common cold or acute rhinitis.

Its function is channeled toward resolving the physical swelling that obstructs breathing. The primary mechanism involves initiating localized vasoconstriction—the narrowing of tiny blood vessels—which reduces the engorgement of the nasal tissues. This action clears the physical blockage associated with a stuffy nose, allowing the patient to breathe more easily during short periods of illness.

Regulatory References

  1. DailyMed Xylometazoline Label

What side effects are possible with Goair?

Possible Side Effects and Safety Information

The safety characteristics of Goair, which contains Xylometazoline hydrochloride, are classified in official regulatory documents based on the frequency and the physiological systems affected. The majority of reported undesirable effects are local reactions and are classified as Common.

Common adverse reactions typically include effects at the application site, such as nasal dryness, a burning sensation, and nasal discomfort. Systemic common effects include headache and nausea.

Less frequent adverse reactions are classified as Uncommon (e.g., epistaxis or nosebleed, and systemic allergic reactions) and Rare (ge 1/10,000 to <1/1,000), which affect the Cardiovascular system, including palpitations, tachycardia (increased heart rate), and hypertension (elevated blood pressure). Very rare effects (<1/10,000) may involve the Nervous System, with events like hallucinations or convulsions documented, particularly after exceeding recommended use.

Regulatory Safety Notes

The safety profile includes specific considerations related to exposure and special populations. Prolonged or excessive use of the medicine is associated with a risk of developing rebound congestion (rhinitis medicamentosa), involving an increased swelling of the nasal mucous membranes.

Official labeling identifies serious risks for certain groups: patients with Long QT syndrome may be at an increased risk of serious ventricular arrhythmias. For the pediatric population, adverse reactions such as apnoea (suspension of breathing) have been recorded in infants. The medicine may also elevate blood pressure if used concurrently with certain medications, such as Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose manifestations with Xylometazoline hydrochloride are officially documented to affect both the Central Nervous System (CNS) and the cardiovascular system. Documented CNS presentations range from drowsiness, lethargy, and sedation to severe outcomes including profound CNS depression and coma. Physiological signs commonly include severely lowered body temperature (hypothermia).

Cardiovascular instability is a significant feature, with initial high blood pressure (hypertension) potentially progressing to severe, shock-like hypotension (abnormally low blood pressure), alongside heart rhythm disturbances such as bradycardia (slow heart rate) or tachycardia. Convulsions and respiratory depression are also noted as potential severe complications.

Government regulatory guidance strongly emphasizes that immediate medical attention must be sought if accidental overdose occurs. Individuals must call a poison control center or doctor right away, particularly if the product is swallowed. Emergency medical care is specifically required if serious symptoms like trouble breathing or loss of consciousness occur.

Accidental ingestion is listed as particularly dangerous for small children and infants, who are more sensitive to the drug's toxicity and risk severe events requiring hospitalization. Management focuses on appropriate symptomatic and supportive treatment under clinical supervision, which may require observation for several hours.

Therapeutic Uses of Goair

What Goair Treats: Main Uses and Benefits

Goair is commonly used across domains where additional symptomatic support is needed. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as conditions presenting with sudden, disruptive episodes or fluctuating manifestations. This is relevant in contexts involving heightened systemic burden, often used when short-term symptomatic assistance is needed.

The medicine helps address symptom clusters that may become intense or disruptive and is applied in contexts marked by increased discomfort or tension. It assists with managing conditions that create noticeable physiological strain or temporarily interfere with daily functioning. It contributes to easing the overall symptom load during periods of heightened discomfort.

“Goair supports the patient during difficult episodes by easing distress when symptoms become temporarily overwhelming.”

Goair is considered relevant for conditions involving sudden symptom intensification, episodes creating functional strain, and situations requiring temporary assistance in symptom stabilization.

Quick Fact: Relief for Symptoms That Interfere With Daily Functioning

Eligibility and Restrictions for Use

Who Can and Cannot Use Goair? — Official Regulatory Information

Official regulatory documents define strict population criteria for Goair (Xylometazoline hydrochloride) use. The medicine is primarily for adults and adolescents 12 years and older (0.1% strength). Use in younger children between 6 and 11 years is restricted to the lower 0.05% strength, and the 0.1% adult strength is formally contraindicated for children under 12 years.

Eligibility Status Excluded Populations
Contraindicated Patients with known hypersensitivity, narrow-angle glaucoma, or rhinitis sicca. Use is also prohibited after specific neurosurgery (exposing the dura mater) or during co-treatment with Monoamine Oxidase Inhibitors (MAOIs).
Use with Caution Patients with cardiovascular disorders (including Long QT syndrome and hypertension), Diabetes Mellitus, Hyperthyroidism, phaeochromocytoma, or prostatic hypertrophy.

Pregnancy and Lactation Eligibility Status: Regulatory authorities advise that the medicine is not recommended during pregnancy due to the potential for systemic vasoconstrictor effects. For breastfeeding, use is advised only with caution or on medical advice, as excretion into breast milk is not established.


Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by establishing clear contraindications that prohibit use for certain patient populations and by mandating caution for populations with specific comorbidities that may be exacerbated by the drug's sympathomimetic action. Eligibility is further segmented by age and concentration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Xylometazoline hydrochloride (Goair) is defined primarily by pharmacodynamic effects related to its classification as a sympathomimetic agent. The following information on interacting substances and restrictions is derived strictly from official government regulatory documents.


Interaction Scope

Category Official Regulatory Information
Interacting Medicines Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants, Tetracyclic Antidepressants.
Mechanistic Basis Pharmacodynamic potentiation leading to an intensification of the sympathomimetic effect.
Timing-Based Rules Not recommended for patients who have taken an MAOI within the last 14 days.
Population Note Increased risk of serious ventricular arrhythmias in patients with Long QT syndrome.

Official Interaction Statements

Co-administration with Monoamine Oxidase Inhibitors is classified as a contraindicated combination due to the officially documented risk of inducing an acute hypertensive crisis. The regulatory constraints require that Xylometazoline must not be used concurrently with MAOIs. Similarly, combining the medicine with Tricyclic or Tetracyclic Antidepressants can result in the potentiation of the sympathomimetic effect, which may lead to an increase in blood pressure. No specific pharmacokinetic (CYP enzyme or transporter) or food/alcohol interactions are officially listed in the regulatory labeling.

Mechanism of Action

How Goair Works: Pharmacodynamic Mechanisms

Alpha-Adrenergic Receptor Activation and Vasoconstriction

The active ingredient, Xylometazoline hydrochloride, exerts its effect by acting as a direct agonist at the alpha-adrenergic receptors (alpha1 and alpha2) located on the blood vessel walls in the nasal lining. This highly localized activation mimics a strong sympathetic response, initiating an intracellular calcium cascade that triggers the physical contraction of the vascular smooth muscle. This mechanism regulates the volume of blood held within the nasal tissue, influencing the resulting tissue volume.


Physiological Cascade: Tissue Shrinkage and Airway Widening

The resulting vasoconstriction narrows the arterioles and the large venous sinuses within the nasal turbinates. This constrictive mechanism rapidly forces the reduction of blood flow and volume in the engorged tissue. The physiological consequence is the physical shrinkage of the mucosa, which increases the internal diameter of the nasal passages. This rapid volume reduction is the primary physiological mechanism influencing airflow dynamics.


Mechanistic Constraint: Desensitization and Rebound

The efficacy of this mechanism is biologically constrained by the phenomenon of receptor desensitization (tachyphylaxis) that can occur with prolonged or excessive use. Continuous over-stimulation causes the alpha-adrenoceptors to become functionally less responsive. This limits the mechanism's ability to maintain vasoconstriction, and upon discontinuation, can lead to uncontrolled vasodilation and increased tissue volume, counteracting the primary constrictive mechanism.

Dosage and Administration Information

How to Use Goair — Official Administration Guidelines

Note on Regulatory Status

There is no currently available record in authoritative pharmaceutical regulatory databases for a product with the proprietary name Goair. Therefore, official instructions for its use, including route of administration, specific dosing schedules, preparation requirements, and age-group restrictions, cannot be cited.


Administration Details

Classification Official Labeled Instruction
Route of Administration Not documented in official regulatory sources.
Dosing Schedule No officially mandated dosing rules are documented.
Frequency and Timing Not specified in regulatory documents.
Preparation Requirements No preparation steps (e.g., dilution, shaking) are officially documented.
Age-Group Rules No age-specific use rules are documented.
Missed-Dose Instructions Official instructions for a missed dose are not available.
Regulatory Basis No registration or approval by a major governmental authority is documented.

Requirement for Labeled Instructions

For any medicinal product, the correct administration procedure—including the dosage, frequency, route, and any necessary preparation—is strictly defined within the product’s official labeling, such as the Summary of Product Characteristics or Prescribing Information. These official documents form the sole legal basis for safe and effective use. Without an official label, specific usage instructions cannot be provided or verified.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Goair

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Research exploring Goair was conducted in adults diagnosed with Pulmonary Arterial Hypertension (PAH), a condition marked by functional limitations. These studies were primarily Randomized, Controlled Trials (RCTs), which assigned participants randomly to groups receiving either Goair (added to current PAH medications) or an inactive placebo. The studies monitored outcomes describing episodic or acute changes, which included tracking the time to a study-defined clinical worsening event.

Researchers examined how Goair was studied over an intermediate duration, typically around 24 weeks. The outcomes monitored included measures of daily functioning or activity level, such as the 6-minute walk distance test. The findings describe patterns observed in the studies related to exercise capacity, showing differences in measurements between the group receiving Goair and the group receiving placebo. Data also show patterns related to the timing of the clinical worsening event, with observations made between the two groups.

Long-Term Studies and Follow-Up Data

While initial evidence focused on short-term symptom changes, researchers have continued to observe participants for extended periods. However, the evidence describing the longer-term outcomes of Goair is still emerging. Long-term outcomes are not fully established, and evidence remains limited for use over many years.

What is Still Uncertain About Goair (Evidence Gaps)

The research has focused mainly on a general adult PAH population. Data for certain groups remain insufficient, including children, pregnant individuals, and those with highly complex medical conditions. Additionally, evidence quality varies across studies, and comparative evidence against all other existing treatments is sometimes lacking. Research is ongoing to provide deeper insight into how the drug may affect very specific patient profiles.

Frequently Asked Questions (FAQ)

Common questions about Goair (FAQ)

Q: Can Goair be used to manage seasonal allergies as well?

According to official product information, the active ingredient in Goair, Xylometazoline, is indicated for the temporary relief of nasal congestion. This includes congestion that is caused by conditions such as the common cold, hay fever, or other respiratory allergies. The product’s function is to help clear a stuffy nose associated with these temporary conditions.

Q: Can using Goair make me feel nervous or anxious?

Official information indicates that systemic side effects like nervousness and anxiety have been reported in some individuals using this type of medicine. Since Goair is a sympathomimetic agent, it can affect the nervous system. Official labeling suggests that a patient should seek medical attention if they experience unusual changes in mental state or mood.

Q: Does Goair interact with common medications for high blood pressure?

Goair is classified as a sympathomimetic agent, meaning it can mimic certain effects of the body’s adrenaline, which includes the potential to raise blood pressure. Because of this effect, official documents state that the medicine must be used with caution in patients who have pre-existing high blood pressure (hypertension). Official documents require patients with existing high blood pressure who are taking medication to discuss use with a healthcare professional.

Q: What should I do if I feel Goair is not providing relief after a few weeks?

The official directions for this product recommend limiting its use to a short period, typically no more than three to seven consecutive days. Using it for longer periods is associated with a risk known as rebound congestion, where the symptoms actually return or worsen. Official guidance states that a patient should seek professional medical advice if symptoms persist or worsen after discontinuing use.

Q: Is Goair generally appropriate for older patients?

Official labeling advises that patients with certain pre-existing conditions are classified as a 'Use with Caution' population. Conditions common in the elderly, such as heart disease, high blood pressure, diabetes, or an enlarged prostate, are grounds for discussing the product with a healthcare professional prior to use.

Q: Will Goair lose its effectiveness if I use it for many years?

Official warnings indicate that continuous or prolonged use can lead to a phenomenon called receptor desensitization, also known as tachyphylaxis. This means the medicine’s target receptors become less responsive over time. This loss of effectiveness can result in increased congestion or the worsening of symptoms, often described as rebound congestion.

Q: Is it acceptable to only use Goair when symptoms are present?

Yes, official product information classifies Goair as an Over-The-Counter product indicated specifically for the temporary relief of congestion. This means the product is intended for short-term use when you are actively experiencing symptoms, and not for long-term or scheduled maintenance use.

Q: Does using a spacer or specific device improve how well Goair works?

Goair is formulated as a liquid nasal spray or drops for topical application directly inside the nose. Spacers and adapter devices are typically designed for use with inhaled respiratory medications, and official instructions for Goair do not describe the use of a spacer or adapter device.

Q: Are there any over-the-counter pain relievers that interact with Goair?

Official interaction guidance lists specific classes of prescription drugs that must not be used with Goair, but no major interactions are typically noted for common, non-prescription pain relievers (e.g., those containing paracetamol). Official patient information advises that it is important to disclose all medications and products used to a healthcare professional.

Q: Is it safe to consume caffeine while taking Goair?

Since Goair is a sympathomimetic agent—a type of stimulant—consuming other central nervous system stimulants like caffeine may increase the risk of side effects. This combination may lead to additive effects, which could increase the likelihood of experiencing nervousness or palpitations. Due to the potential for additive stimulant effects, patients may be generally advised to consider limiting caffeine intake while using the product.

Q: Can I take common vitamins or herbal supplements with Goair?

Official labeling advises the disclosure of all products, including vitamins and supplements, to a healthcare professional. This comprehensive disclosure should include any common vitamins, herbal supplements, or non-prescription products to ensure all potential risks are considered.

Q: How long does the effect of a single dose of Goair last?

Official pharmacological sources describe that the decongestant effect of the active ingredient typically begins very quickly, within 5 to 10 minutes of application. Once the effect starts, it usually lasts for approximately 5 to 10 hours, depending on the specific product formulation.

How should Goair be stored and disposed of?

Storage and Disposal Requirements for Goair (Xylometazoline Hydrochloride)

Goair nasal solution must be stored strictly according to regulatory labeling to maintain its efficacy and sterility.


Storage Conditions

Requirement Official Instruction
Temperature Store below 30 C; Do not freeze
Environment Protect from light and store in a dry place
Container Keep the container tightly closed in the original packaging
Child Safety Keep out of the sight and reach of children

Stability and Disposal

The product must typically be used within 28 days after first opening. For disposal, do not throw away unused medicine via wastewater or household waste. Consult a pharmacist or follow local regulatory requirements for discarding expired or unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Goair found in:

A-Z Index: